1. Home
  2. ADPT vs SCL Comparison

ADPT vs SCL Comparison

Compare ADPT & SCL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • ADPT
  • SCL
  • Stock Information
  • Founded
  • ADPT 2009
  • SCL 1932
  • Country
  • ADPT United States
  • SCL United States
  • Employees
  • ADPT N/A
  • SCL N/A
  • Industry
  • ADPT Biotechnology: Biological Products (No Diagnostic Substances)
  • SCL Package Goods/Cosmetics
  • Sector
  • ADPT Health Care
  • SCL Consumer Discretionary
  • Exchange
  • ADPT Nasdaq
  • SCL Nasdaq
  • Market Cap
  • ADPT 1.4B
  • SCL 1.2B
  • IPO Year
  • ADPT 2019
  • SCL N/A
  • Fundamental
  • Price
  • ADPT $9.53
  • SCL $53.06
  • Analyst Decision
  • ADPT Buy
  • SCL
  • Analyst Count
  • ADPT 6
  • SCL 0
  • Target Price
  • ADPT $9.83
  • SCL N/A
  • AVG Volume (30 Days)
  • ADPT 2.5M
  • SCL 134.8K
  • Earning Date
  • ADPT 05-01-2025
  • SCL 04-29-2025
  • Dividend Yield
  • ADPT N/A
  • SCL 2.84%
  • EPS Growth
  • ADPT N/A
  • SCL 47.62
  • EPS
  • ADPT N/A
  • SCL 2.45
  • Revenue
  • ADPT $189,527,000.00
  • SCL $2,222,111,000.00
  • Revenue This Year
  • ADPT $25.00
  • SCL $9.39
  • Revenue Next Year
  • ADPT $20.38
  • SCL $6.37
  • P/E Ratio
  • ADPT N/A
  • SCL $22.16
  • Revenue Growth
  • ADPT 8.61
  • SCL N/A
  • 52 Week Low
  • ADPT $2.99
  • SCL $44.23
  • 52 Week High
  • ADPT $10.28
  • SCL $94.77
  • Technical
  • Relative Strength Index (RSI)
  • ADPT 59.79
  • SCL 47.36
  • Support Level
  • ADPT $8.50
  • SCL $53.55
  • Resistance Level
  • ADPT $9.69
  • SCL $56.85
  • Average True Range (ATR)
  • ADPT 0.41
  • SCL 1.25
  • MACD
  • ADPT -0.01
  • SCL -0.19
  • Stochastic Oscillator
  • ADPT 77.52
  • SCL 0.00

About ADPT Adaptive Biotechnologies Corporation

Adaptive Biotechnologies Corp is a company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is test authorized by the FDA for the detection and monitoring of minimal residual disease (MRD) in patients with multiple myeloma (MM), B cell acute lymphoblastic leukemia (ALL) and chronic lymphocytic leukemia (CLL) and is also available as a CLIA-validated laboratory developed test (LDT) for patients with other lymphoid cancers, including diffuse large B-cell lymphoma (DLBCL).

About SCL Stepan Company

Stepan Co manufactures and sells a variety of chemicals and chemical-based products. The company organizes itself into three segments based on product type. The surfactants segment, which generates the majority of revenue, sells cleaning agents used in detergents, shampoos, body wash, fabric softeners, toothpastes, and other personal-care products. Surfactants are chemical agents that affect the interaction between two surfaces. The polymers segment sells polyurethane used to manufacture rigid foam for thermal insulation, as well as phthalic anhydride used to make plastic components for the construction, automotive, and boating industries. The specialty products segment sells chemicals used in food and flavoring. Majority of Stepan's revenue comes from the United States.

Share on Social Networks: